Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | GALR1 | P47211 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1513411 | 0.80 | BRD4 (0.48) | GALR1TP53POLBHPGDMAPT | |
| SCHEMBL1513235 | 0.78 | NPC1 (0.47) | NPC1RAB9ACASP3ATMSENP8 | |
| SCHEMBL1513221 | 0.77 | NPC1 (0.46) | NPC1RAB9ACASP3ATMSENP8 | |
| SCHEMBL29617015 | 0.75 | TP53 (0.62) | NPC1RAB9AGALR1TP53POLB | |
| SCHEMBL14759026 | 0.74 | CYP1A2 (0.53) | NPC1RAB9ACASP3ATMSENP8 | |
| SCHEMBL4901644 | 0.74 | TP53 (0.50) | NPC1RAB9AGALR1TP53POLB | |
| SCHEMBL4193217 | 0.73 | TP53 (0.61) | GALR1TP53POLBHPGD | |
| SCHEMBL1513323 | 0.73 | GALR1 (0.48) | NPC1RAB9ACASP3ATMSENP8 | |
| SCHEMBL1279251 | 0.72 | TP53 (0.46) | NPC1RAB9ATP53POLBHPGD | |
| SCHEMBL1513281 | 0.72 | CDK8 (0.50) | NPC1RAB9ATP53POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130384-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-02 | — | — | US | disclosed |
| EP-2298731-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130384-A1 | AMIDE COMPOUND | GPR52, CNR2, ARRB1 | NPC1 2004/4885RAB9A 3900/4885CASP3 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.